Loading
A phase 2 trial of Evorpacept, Pembrolizumab in head and neck squamous cell carcinoma, run by ALX Oncology Inc., active and no longer recruiting.
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) is a phase 2 interventional study registered as NCT04675294 by ALX Oncology Inc., with 189 participants enrolled, started 2021-04-02 and due to reach its primary completion in 2025-03-03. Interventions recorded: evorpacept, pembrolizumab. Conditions listed: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade, Head and neck squamous cell carcinoma.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade.
Shares ALX Oncology, Evorpacept, CD47 and SIRP-alpha blockade.
Shares ALX Oncology, Evorpacept.
Shares ALX Oncology, CD47 and SIRP-alpha blockade.